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SUMMARY.-It has been shown that when 32p counting from a tumour is
continuous peaks in the count rate can sometimes be induced by large doses
of nicotinic acid, nicotinamide or 3-acetylpyridine, but not by 6-aminonicotin-
amide. These 32p counting peaks have been associated with the time of
maximal new synthesis of nicotinamide adenine dinucleotide (NAD). Sen-
sitization to irradiation or some cytotoxic drugs has been found at the peak
of this new NAD synthesis. The radioprotective agents cysteamine, 2-amino-
ethylisothiouronium bromide (AET) and serotonin have been found to cause
a rapid fall in tissue NAD levels. The results have been briefly discussed.
THE continuous counting of 32P from tumours by way of an embedded Geiger
counter was first described by Hale (1961). Later, Bullen, Freundlich, Hale,
Marshall and Tudway (1963) concluded from clinical experience with the technique
that a peak in 32P activity coincided with a period of relative radiosensitivity
whilst a trough in activity coincided with a period of relative radioinsensitivity.
Studies with experimental tumours in animals were made by Bleehen, Bryant
and Gallear (1967), Calcutt, Bullen, Marshall and Godden (1967) and Woolley-
Hart, Twentyman, Corfield, Joslin, Morrison and Fowler (1968). All these
groups found fluctuations to occur in 32P counting rates from tumours. Whilst
the exact nature of these fluctuations has not been identified Taylor, Parker,
Field and Greatorex (1968) have concluded that they are metabolic in origin.
Extension of this work has now led to the discovery that compounds inducing
a new synthesis of nicotinamide adenine dinucleotide (NAD, diphosphopyridine
nucleotide or coenzyme I) will induce peaks in the 32p counting rate from tumours.
This finding has allowed experimental test of the clinical impression of radio-
sensitivity at the times of such peaks.
32P uptake studies
Mice of either sex implanted with transplantable tumours have been used in
conjunction with B.I.N. (Twentieth Century Electronics) miniature Geiger
counters. Instrumentation was as described by Calcutt et al. (1967). Each
animal was given P2p by intraperitoneal injection of a solution of radioactive
sodium phosphate in distilled water at the rate of 1 /aCi per 100 g. ofbody weight.
Further experiments were only carried out when a stable trace had been obtained
for at least 24 hours.
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nicotinic acid in high doses (200-600 mg./kg.) caused transient rises in the 32P
count sonme 3-4 hours after intraperitoneal injection. That this peaking in the
32P count was due to the known vasodilatory action of nicotinic acid seemed
unlikely in view ofthe relatively long time delay. This explanation was discarded
finally when it was found that the related-but non-vasodilatory-agent nicotin-
amide caused a similar response in the 32P count. Extension ofthis work resulted
in the finding that the anti-vitamin 3 acetylpyridine also caused peaks in the
32P traces. On the other hand the alternate anti-vitamin 6 aminonicotinamide
was found to have no effects whatever on 32P traces when tested against a series
of different tumours. It was noticeable in these studies that response in the
32P trace was not invariable. It actually occurred in some two-thirds of the
tumours tested and to date the occurrence or otherwise of response is still unpre-
dictable. The time at which any response occurred was somewhat variable.
Usually about 3-4 hours after injection of the eliciting agent it could on occasion
be delayed or even occur earlier.
Tumour NAD levels
The three agents found successful in eliciting peaks in the 32P count rates are
all known to cause a new synthesis of NAD (see review by Shuster, Langham,
Kaplan and Goldin (1958)) whilst the fourth-6 amino-nicotinamide-which was
inactive was found by Shapiro, Dietrich and Shils (1957) to have no effects on
tissue NAD levels. The possibility of an association between tumour phosphate
and tumour NAD levels after treatment with agents causing new synthesis of
NAD was examined. Measurements of NAD by the enzymatic technique of
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FIG. 1. The response of Harding-Passey melanoma to 3 acetylpyridine (60 mg./kg.) by
intraperitoneal injection at time indicated by arrow.
A 32p trace from tumour by way of embedded Geiger counter. Parallel lines indicate
±3 standard deviations of local mean count rate.
B Tumour NAD levels.
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Klingenberg (1965) in tumours from animals pretreated with nicotinamide,
nicotinic acid or 3-acetylpyridine showed that maximal levels of NAD occurred
at the times of 32p peaks, or a little earlier. Some results are illustrated in
Fig. 1. Similar findings have been made with skin carcinoma P.L. 64, sarcoma
Bp. 64/12 and the Crocker sarcoma S.180.
Radiosensitisation experiments
In an initial series of experiments whole body sensitisation was investigated.
Using 14-week-old BALB/c mice an LD50/30 of 715 rads of 6OCo gamma rays
was found. A further 120 mice were then treated in groups of 20 with single
doses of 60Co gamma rays above and below this LD50/30 dose. Half of each
group of animals was given a single dose of nicotinamide by intraperitoneal
injection 32 hours before irradiation. The LD50130 was calculated from a probit
plot of the surviving fraction from each group. The lowering of the LD50/30 by
pretreatment with nicotinamide is shown in Table I, together with data showing
TABLE I. The Response of BALB/c Mice to Whole Body Irradiation
32 Hours After Pretreatment with Nicotinamide
Ratio of weight loss
Dose of Change in treated
nicotinamide LD50 (rads) controls at 50
(mg./kg.) after 8 days
200 35 1 40
400 65 1 65
600 -50 1 60
800 . -45 153
an increased post irradiation weight loss in the pretreated animals. Irradiated
control mice lost about 2* 5 g. (100% body weight) at 8 days post irradiation and
about 8X0 g. (350o body weight) just before death. Whilst the reductions in
LD50 and the increased weight losses appear consistent with one another they
do not appear to be consistent with the increased doses of nicotinamide. They
do, however, appear consistent with the level of induced NAD since Shuster
et al. (1958) have found NAD synthesis to increase with increasing nicotinamide
dosage to a maximum with a nicotinamide dosage of 450 mg/kg. Further increase
in the nicotinamide dosage leads to a decline in NAD synthesis.
That the above results were not due to a toxic action of the nicotinamide is
shown by the fact that nicotinamide at 450 mg./kg. causes a slight increase in
the weight of treated mice as compared with untreated controls.
Tumour sensitisation has been investigated with Crocker S.180 tumours
transplanted in the flanks of BALB/c mice. Pairs of tumours matched for
size (less than 250 mm3) were selected and one animal was given nicotinamide
(400 mg./kg.) by intraperitoneal injection. The paired tumours were irradiated
321 hours later with 95 kV X-rays at 165 rad/min. Body shielding was with
4 mm. lead in the form of a tube and the tumour was pulled through a slot in
the lead. Twenty-five pairs of tumours have been treated in this fashion with
doses ranging from 3 to 5-2 krads, each dose being given in equal fractions in
two or three different axes. Of the 25 control tumours four regressed completely,
four persisted without growth for 21 days and the remainder renewed growth
after a temporary check. Of the 25 pretreated with nicotinamide 24 regressed
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completely leaving a scar whilst one grew without check. This last result may
have been the consequence of a laboratory error in coding the animals. Two
animals from this series have since shown further tumour growth, in each case
in an unirradiated area. Both cases have probably arisen from tumour fragments
left in the trochar track during the original transplantation. Currently, some
animals have survived more than 6 months with no recurrence of their tumour.
The tumour growth patterns of a pair oftumours and ofone completely untreated
tumour are shown in Fig. 2. The appearance of one experiment 21 days after
irradiation is illustrated in Fig. 3.
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FIG. 2. Growth rates of sarcoma S.180.
A Untreated tumour.
B Tumour treated with 4- 5 krads.
C- Tumour treated with nicotinamide (400 mg./kg.) 31 hours before 45 krads.
A series of experiments in which nicotinamide was given immediately before
irradiation showed that treatment at this time had no apparent effect on the
ultimate response to irradiation.
Sensitisation to cytotoxic drugs
Because of the similarities in effects of irradiation and certain cytotoxic
compounds the possibility of sensitisation to cytotoxic drugs has been examined.
Initial experiments with the NK lymphoma (ascites) in BALB/c mice and used
5 days after transplant of 106 cells showed that sensitisation occurred 3- hours
after treatment with nicotinamide (600 mg./kg.), 3 acetylpyridine (60 mg/kg.)
or nicotinic acid (400 mg./kg.). Results in the case of nitrogen mustard (HN2)
and nicotinamide are illustrated in Fig. 4. This also shows that nicotinamide
alone causes an increase in tumour growth as compared with untreated controls,
and that at the maximum tolerated dose (3 mg./kg.) there is a reversal of the
effect and some apparent protection. This happening has occurred in about
one third of our experiments and is, so far, unexplained.
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FIG. 4.-Dose response curve of NK lymphoma treated with nitrogen mustard (HN2) 5 days
after transplant.
A-Normal tumour.
B-Normal tumour treated 3i hours previously with nicotinamide (600 mg./kg.).
Experiments in which the nicotinamide was given at other times (0-5 hours)
before treatment with nitrogen mustard showed very little or no alteration in
the response. On the other hand nicotinamide (600 mg./kg.) given up to 3 hours
after the nitrogen mustard has resulted in an apparent protection. This, however,
may not be a true post treatment protection but merely enhanced growth of
residual undamaged cells induced by nicotinamide treatment.
Further work has resulted in the sensitisation of the NK lymphoma (ascites),
sarcoma S.180 and skin carcinoma P.L.64 against nitrogen mustard, thiotepa
and 2-amino-cyclopentanecarboxylic acid (A.C.P.C.). No effects on the response
to methotrexate have been found. Using a line of the NK lymphoma rendered
resistant (and cross resistant to many other agents) by long continued treatment
with Degranol (mannomustine hydrochloride) a return to near the sensitivity of
thenormal tumourline was achieved by treatment with nicotinamide (600 mg./kg.)
31 hours before giving Degranol.
The results ofanother experiment with the resistant line ofthe NK lymphoma
are shown in Fig. 5. Groups of 5 mice transplanted with 106 tumour cells 5 days
earlier have been treated with nitrogen mustard (15 mg./kg.) at intervals after
intraperitoneal injection ofnicotinamide (450 mg./kg.). The results as measured
8 days later are compared with the tumour response in terms of new NAD syn-
thesis. It will be seen that in this case the nicotinamide itself caused a slight
EXPLANATION OF PLATE
FIG. 3.-Appearance of mice bearing sarcoma S.180, 21 days after treatment. Tumour in
both cases of 1 cm3 volume at time of treatment.
A-3 0 krads irradiation.
B-3* 0 krads irradiation 31 hours after intraperitoneal injection of nicotinamide (400
mg./kg.).
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FIG. 5.-Response of resistant line of NK lymphoma to nitrogen mustard after nicotinamide
(45;0 mg./kg.) pretreatment.
A-Tumour response at various times after pretreatment.
B-Tumour NAD levels after treatment with niicotinamide (450 mg./kg.).
reduction in tumour growth, some sensitisation occurred and that this was closely
associated in time with the maximal NAD response.
This tumour is also interesting in that it has a very high basal level of NAD.
Experimnents with radioprotective agents
Since Calcutt et al. (1967) showed that the powerful radioprotectors, cyste-
amine and 2-aminoethylisothiouronium bromide (AET) will cause rapid falls in
32p counting rates from tumours at times covering the period of maximal protec-
tion the effect of these compounds on tissue NAD levels has been examined.
Using the technique of Klingenberg (1965) NAD has been estimated in the livers
of rats and mice at various short intervals after giving radioprotective doses of
cysteamine, AET or serotonin (5-hydroxytryptamine). All three have been
found to cause a rapid and profound fall in NAD levels. Cysteamine has also
been found to cause a rapid loss of NAD in rat spleen. Results for cysteamine
on rat and mouse liver are shown in Fig. 6 where it will be noticed that the effect
is more pronounced in mouse than in rat liver, which may be associated with the
fact that cysteamine is a better protector of mice than rats (see Bacq, 1965,
p. 130).
DISCUSSION
Although the results given above only represent an interim report on work
still in progress they are already so well defined as to merit further consideration.
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FIG. 6.-Liver NAD levels after intraperitoneal cysteamine (150 mg./kg.).
A-Rat liver-control 180+16 sug. NAD per 1 g. wet weight of liver.
B-Mouse liver-control 175+33 ,ug. NAD per 1 g. wet weight of liver.
The three agents acting as sensitisers appear to do so by indirect action of
inducing synthesis of new NAD and since sensitisation has only been found at
the peak ofthe new NAD synthesis it would seem that the NAD is the proximate
sensitiser. This conclusion is supported by the finding that the potent radio-
protective agents cysteamine, AET and serotonin all cause an immediate loss
of NAD. The period during which NAD is low is the one during which radio-
protection is maximal. To date we have been unable to find any association
between normal tissue levels of NAD and the response to irradiation or drugs.
It appears that a change from the level of the normal balanced system ofcellular
biochemistry is essential in order to influence the response to irradiation or
drugs. This question is being investigated in further detail.
There are two further points which are in keeping with a direct role for NAD
in the response to external agents. Land and Swallow (1968) have shown that
NAD can be reduced by hydrated electrons and that a very rapid and efficient
intramolecular electron transfer occurs. Since under in vivo conditions a consider-
able amount of NAD exists in association with proteins the possibility of further
intermolecular transfer cannot be discounted. Thus the absolute amount of
NAD could influence the extent of primary damage. Secondly, NAD is the
requisite coenzyme for many oxidative systems, so a change in NAD levels
would be expected to influence metabolic processes and consequently affect the
extent of fixation ofprior damage, or equally, to affect recovery processes.
The nature of the relationship between changes in NAD levels and the
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apparently associated changes in phosphate levels, as indicated by 32P counts,
remains a matter of conjecture. Certainly, the actual amounts of phosphate
involved are very much greater than can be accounted for as the phosphate
groups of the NAD concerned. The phosphate level changes although, as pre-
viously mentioned, unpredictable in their occurrence have proved an adequate
indication of the timing of the NAD changes and have allowed the setting up of
an experimental system to test for radiosensitisation at the times of peak activity
of phosphorus. The success of these experiments makes it appear that the
opinion of Bullen et al. (1963) based on clinical data and spontaneous phosphorus
level changes, that a peak in 32p counting rates from tumours represents a time
of radiosensitivity could be well founded.
The role of sulphydryl (-SH) groups in determining the response to irradiation
(Bacq, 1965) or to cytotoxic drugs (Calcutt and Connors, 1963) has been the
subject of much inconclusive work in the past. With the current demonstration
that cysteamine and AET, both known to affect cellular -SH levels during the
period of protection, also affect cellular NAD at the same time the problem
of interrelationships between -SH and NAD is raised. The associated changes
in phosphate levels must also be considered. Although lack ofevidence precludes
further discussion now this situation emphasises the need to consider cell bio-
chemistry as an integrated system rather than in terms of isolated entities.
Both nicotinic acid and nicotinamide are freely available, widely used pharma-
ceuticals which are tolerated in large doses by human beings. In the light of the
above experimental findings it is necessary to emphasise that the uncontrolled
use of these or related compounds in conjunction with radiotherapy or cytotoxic
drugs could lead to unexpected results.
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